https://www.selleckchem.com/pr....oducts/geldanamycin.
5] vs 46 [Q1Q3 28, 76.5] days; median ICU LOS 15 [Q1Q3 10, 28.75] vs 26 [Q1Q3 17, 43] days; mortality 12.3% (95%CI 7.9-16.8) vs 16.7% (95%CI 13.6-19.7). The incidence of VA-HARTI decreased over ten years while NVA-HARTI incidence did not change. VA-HARTI was an independent risk factor of death, OR 1.54 (1.11-2.14), while NVA-HARTI was not. Our findings suggest that NVA-HARTI in neurocritical care patients represents a significant healthcare burden with relatively high incidence and associated poor outcomes. Unlike VA-HARTI, the inc
Gefällt mir
Kommentar
Teilen
